Hypoxia-inducible factor-2α is essential in activating the COX2/mPGES-1/PGE2 signaling axis in colon cancer

Carcinogenesis

Volumn 34, Issue 1, 2013, Pages 163-169

  Xue, Xiang ^a   Shah, Yatrik M ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; HYPOXIA INDUCIBLE FACTOR; HYPOXIA INDUCIBLE FACTOR 2ALPHA; NIMESULIDE; PROSTAGLANDIN E SYNTHASE 1; PROSTAGLANDIN E1; PROSTAGLANDIN E2; VON HIPPEL LINDAU PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLON ADENOCARCINOMA; COLON CANCER; COLON CARCINOGENESIS; COLON MUCOSA; CONTROLLED STUDY; GENE DISRUPTION; GENE EXPRESSION REGULATION; GENE INDUCTION; GENE OVEREXPRESSION; GENE TARGETING; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MICROSOME; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION;

ANIMALS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CHROMATIN IMMUNOPRECIPITATION; CHROMATOGRAPHY, LIQUID; COLONIC NEOPLASMS; CYCLOOXYGENASE 2; MASS SPECTROMETRY; MICE; PROSTAGLANDINS; SIGNAL TRANSDUCTION;

EID: 84872130484     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgs313     Document Type: Article

References (56)

1. Eberhart, C.E. et al. (1994) Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology, 107, 1183-1188.
2. Jakobsson, P.J. et al. (1999) Identification of human prostaglandin E synthase: a microsomal, glutathione-dependent, inducible enzyme, constituting a potential novel drug target. Proc. Natl. Acad. Sci. U.S.A., 96, 7220-7225.
3. Murakami, M. et al. (2006) Prostaglandin E synthase: a novel drug target for inflammation and cancer. Curr. Pharm. Des., 12, 943-954.
4. Steinbach, G. et al. (2000) The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N. Engl. J. Med., 342, 1946-1952.
5. Schmedtje, J.F. Jr et al. (1997) Hypoxia induces cyclooxygenase-2 via the NF-kappaB p65 transcription factor in human vascular endothelial cells. J. Biol. Chem., 272, 601-608.
6. Csiki, I. et al. (2006) Thioredoxin-1 modulates transcription of cyclooxygenase-2 via hypoxia-inducible factor-1alpha in non-small cell lung cancer. Cancer Res., 66, 143-150.
7. Kaidi, A. et al. (2006) Direct transcriptional up-regulation of cyclooxygenase-2 by hypoxia-inducible factor (HIF)-1 promotes colorectal tumor cell survival and enhances HIF-1 transcriptional activity during hypoxia. Cancer Res., 66, 6683-6691.
8. Eltzschig, H.K. et al. (2011) Hypoxia and inflammation. N. Engl. J. Med., 364, 656-665.
9. Bertout, J.A. et al. (2008) The impact of O2 availability on human cancer. Nat. Rev. Cancer, 8, 967-975.
10. Semenza, G.L. et al. (1992) A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol. Cell. Biol., 12, 5447-5454.
11. Wang, G.L. et al. (1993) Characterization of hypoxia-inducible factor 1 and regulation of DNA binding activity by hypoxia. J. Biol. Chem., 268, 21513-21518.
12. Ivan, M. et al. (2001) HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science, 292, 464-468.
13. Jaakkola, P. et al. (2001) Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science, 292, 468-472.
14. Wang, G.L. et al. (1993) General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia. Proc. Natl. Acad. Sci. U.S.A., 90, 4304-4308.
15. Wang, G.L. (1995) Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc. Natl. Acad. Sci. U.S.A., 92, 5510-5514.
16. Tian, H. et al. (1997) Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. Genes Dev., 11, 72-82.
17. Loboda, A. et al. (2010) HIF-1 and HIF-2 transcription factors-similar but not identical. Mol. Cells, 29, 435-442.
18. Xue, X. et al. (2012) Hypoxia-inducible factor-2α activation promotes colorectal cancer progression by dysregulating iron homeostasis. Cancer Res., 72, 2285-2293.
19. Shah, Y.M. et al. (2009) Intestinal hypoxia-inducible transcription factors are essential for iron absorption following iron deficiency. Cell Metab., 9, 152-164.
20. Haase, V.H. et al. (2001) Vascular tumors in livers with targeted inactivation of the von Hippel-Lindau tumor suppressor. Proc. Natl. Acad. Sci. U.S.A., 98, 1583-1588.
21. Taylor, M. et al. (2011) Hypoxia-inducible factor-2α mediates the adaptive increase of intestinal ferroportin during iron deficiency in mice. Gastroenterology, 140, 2044-2055.
22. Inoue, H. et al. (1999) Glucocorticoid-mediated suppression of the promoter activity of the cyclooxygenase-2 gene is modulated by expression of its receptor in vascular endothelial cells. Biochem. Biophys. Res. Commun., 254, 292-298.
23. Wang, C.Y. et al. (1996) TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB. Science, 274, 784-787.
24. Brown, J.R. et al. (2005) COX-2: a molecular target for colorectal cancer prevention. J. Clin. Oncol., 23, 2840-2855.
25. Lee, J.J. et al. (2010) Hypoxia activates the cyclooxygenase-2-prostaglandin E synthase axis. Carcinogenesis, 31, 427-434.
26. Sheehan, K.M. et al. (1999) The relationship between cyclooxygenase-2 expression and colorectal cancer. JAMA, 282, 1254-1257.
27. Cesario, A. et al. (2011) The interplay between indoleamine 2, 3-dioxygenase 1 (IDO1) and cyclooxygenase (COX)-2 in chronic inflammation and cancer. Curr. Med. Chem., 18, 2263-2271.
28. Uyttenhove, C. et al. (2003) Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2, 3-dioxygenase. Nat. Med., 9, 1269-1274.
29. Muller, A.J. et al. (2005) Inhibition of indoleamine 2, 3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat. Med., 11, 312-319.
30. Mukherjee, P. et al. (2009) Progression of pancreatic adenocarcinoma is significantly impeded with a combination of vaccine and COX-2 inhibition. J. Immunol., 182, 216-224.
31. Koblish, H.K. et al. (2010) Hydroxyamidine inhibitors of indoleamine-2, 3-dioxygenase potently suppress systemic tryptophan catabolism and the growth of IDO-expressing tumors. Mol. Cancer Ther., 9, 489-498.
32. Hou, D.Y. et al. (2007) Inhibition of indoleamine 2, 3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. Cancer Res., 67, 792-801.
33. Wang, D. et al. (2010) Eicosanoids and cancer. Nat. Rev. Cancer, 10, 181-193.
34. Marnett, L.J. et al. (2002) COX-2: a target for colon cancer prevention. Annu. Rev. Pharmacol. Toxicol., 42, 55-80.
35. Cianchi, F. et al. (2001) Up-regulation of cyclooxygenase 2 gene expression correlates with tumor angiogenesis in human colorectal cancer. Gastroenterology, 121, 1339-1347.
36. Sano, H. et al. (1995) Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res., 55, 3785-3789.
37. Dimberg, J. et al. (1999) Differential expression of cyclooxygenase 2 in human colorectal cancer. Gut, 45, 730-732.
38. Al-Salihi, M.A. et al. (2009) Transgenic expression of cyclooxygenase-2 in mouse intestine epithelium is insufficient to initiate tumorigenesis but promotes tumor progression. Cancer Lett., 273, 225-232.
39. Oshima, M. et al. (1996) Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell, 87, 803-809.
40. Chulada, P.C. et al. (2000) Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice. Cancer Res., 60, 4705-4708.
41. Kamei, D. et al. (2003) Potential role of microsomal prostaglandin E synthase-1 in tumorigenesis. J. Biol. Chem., 278, 19396-19405.
42. Yoshimatsu, K. et al. (2001) Inducible microsomal prostaglandin E synthase is overexpressed in colorectal adenomas and cancer. Clin. Cancer Res., 7, 3971-3976.
43. Sasaki, Y. et al. (2012) Microsomal prostaglandin E synthase-1 is involved in multiple steps of colon carcinogenesis. Oncogene, 31, 2943-2952.
44. Nakanishi, M. et al. (2008) Genetic deletion of mPGES-1 suppresses intestinal tumorigenesis. Cancer Res., 68, 3251-3259.
45. Gordan, J.D. et al. (2007) HIF-2alpha promotes hypoxic cell proliferation by enhancing c-myc transcriptional activity. Cancer Cell, 11, 335-347.
46. Talks, K.L. et al. (2000) The expression and distribution of the hypoxiainducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. Am. J. Pathol., 157, 411-421.
47. Zhong, H. et al. (1999) Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res., 59, 5830-5835.
48. Rigas, B. et al. (1993) Altered eicosanoid levels in human colon cancer. J. Lab. Clin. Med., 122, 518-523.
49. Xia, D. et al. (2012) Prostaglandin E2 promotes intestinal tumor growth via DNA methylation. Nat. Med., 18, 224-226.
50. Hansen-Petrik, M.B. et al. (2002) Prostaglandin E(2) protects intestinal tumors from nonsteroidal anti-inflammatory drug-induced regression in Apc(Min/+) mice. Cancer Res., 62, 403-408.
51. Grimmer, C. et al. (2007) Hypoxia-inducible factor 1alpha is involved in the prostaglandin metabolism of osteoarthritic cartilage through up-regulation of microsomal prostaglandin E synthase 1 in articular chondrocytes. Arthritis Rheum., 56, 4084-4094.
52. Bombardier, C. et al.; VIGOR Study Group. (2000) Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N. Engl. J. Med., 343, 1520-8, 2 p following 1528.
53. Drazen, J.M. (2005) COX-2 inhibitors-a lesson in unexpected problems. N. Engl. J. Med., 352, 1131-1132.
54. Cannon, C.P. et al. (2012) Physiology. COX-2 inhibitors and cardiovascular risk. Science, 336, 1386-1387.
55. Chang, H.H. et al. (2011) Identification and development of mPGES-1 inhibitors: where we are at? Future Med. Chem., 3, 1909-1934.
56. He, S. et al. (2011) Molecular docking and competitive binding study discovered different binding modes of microsomal prostaglandin E synthase-1 inhibitors. J. Chem. Inf. Model., 51, 3254-3261. L. Idhayavani